Kindred Biosciences to Provide Corporate Update via Webcast in Advance of One-on-One Investor Meetings in San Francisco January 12-14, 2016.

San Francisco, CA (January 7, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will provide a corporate update via webcast on Monday, January 11, 2016 in advance of one-on-one investor meetings in San Francisco January 12-14, 2016.

Kindred Biosciences Submits KIND-012 New Animal Drug Application Technical Section for Chemistry, Manufacturing, and Controls to FDA

San Francisco, CA (December 17, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Chemistry, Manufacturing, and Controls (CMC) technical section of the New Animal Drug Application (NADA) for KIND-012. Positive topline results from the pivotal field study […]

Kindred Biosciences Announces Positive Results from Pivotal Study of KIND-012 for Pyrexia in Horses, and Provides Other Product Updates

KIND-012 study meets primary endpoint with p<0.0001. Data to be filed with the FDA for approval. SentiKind study misses primary endpoint. Conference call and webcast scheduled for 5:00 p.m. Eastern Time today. San Francisco, CA (November 16, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, […]

Kindred Biosciences Announces Third Quarter 2015 Financial Results

San Francisco, CA (November 9, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the third quarter ended September 30, 2015 and provided updates on its programs. Development and Corporate Updates KindredBio continues to advance a diversified portfolio of molecules in a capital efficient manner. Some of the recent highlights include: SentiKind™, or […]

Kindred Biosciences Announces Second Quarter 2015 Financial Results

San Francisco, CA (August 10, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the second quarter ended June 30, 2015 and provided updates on its programs. Development and Corporate Updates KindredBio continues to advance a diversified portfolio of validated molecules in a capital efficient manner and has over 20 programs in development. […]